Literature DB >> 19878226

Micropulse diode laser photocoagulation for central serous chorio-retinopathy.

Bhaskar Gupta1, Mohammed Elagouz, Dominic McHugh, Victor Chong, Sobha Sivaprasad.   

Abstract

PURPOSE: Central serous chorioretinopathy (CSC) is usually characterized by a localized detachment of the neurosensory retina that is self-limiting. However, some cases may persist or recur leading to degenerative changes of the retinal pigment epithelium and the neurosensory retina resulting in severe visual loss and requiring intervention.
METHODS: This retrospective case series reports the long-term visual outcome of the use of micropulse laser photocoagulation for this condition with a review of literature.
RESULTS: The mean follow up was 17.1 months. Four of the five patients had complete resolution of symptoms whereas one patient had recurrent CSC from a new leak that failed to resolve after repeat micropulse treatment despite improvement in symptoms. DISCUSSION: The outcomes in this case series confirm the long-term efficacy of micropulse laser in the management of CSC. It produces therapeutic effects that appear comparable to those of conventional photocoagulation with no detectable signs of laser-induced iatrogenic damage.

Entities:  

Mesh:

Year:  2009        PMID: 19878226     DOI: 10.1111/j.1442-9071.2009.02157.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  27 in total

1.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Semiautomated intraocular laser surgery using handheld instruments.

Authors:  Brian C Becker; Robert A MacLachlan; Louis A Lobes; Cameron N Riviere
Journal:  Lasers Surg Med       Date:  2010-03       Impact factor: 4.025

Review 3.  Retinal light toxicity.

Authors:  P N Youssef; N Sheibani; D M Albert
Journal:  Eye (Lond)       Date:  2010-10-29       Impact factor: 3.775

4.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

5.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

6.  Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy.

Authors:  Mehmed Uğur Işık; Mehmet Fatih Kağan Değirmenci; Ayhan Sağlık
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

7.  [Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].

Authors:  I Beger; M J Koss; F Koch
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

8.  Micropulse transscleral cyclophotocoagulation: initial results using a reduced energy protocol in refractory glaucoma.

Authors:  Niten Vig; Sally Ameen; Philip Bloom; Laura Crawley; Eduardo Normando; Alastair Porteous; Faisal Ahmed
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-08       Impact factor: 3.117

9.  Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.

Authors:  Yang Jae Kim; Si Yeol Kim; Seungmin Ha; Daruchi Moon; San Seong; Oh Woong Kwon; Han Sang Park
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

10.  Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.

Authors:  Ju Young Kim; Han Sang Park; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-26       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.